{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:37:09Z","timestamp":1790235429214,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1124\/dmd.123.001270","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T18:05:20Z","timestamp":1683828320000},"page":"1035-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-0081","authenticated-orcid":false,"given":"Trevor N","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M","family":"Howgate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-0647","authenticated-orcid":false,"given":"Saskia N","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rowland Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001270_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40262-019-00825-6","article-title":"A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building","volume":"59","author":"Abduljalil","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200241130-00005","article-title":"Ontogeny of hepatic and renal systemic clearance pathways in infants: part II","volume":"41","author":"Alcorn","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/17425255.2022.2099836","article-title":"Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates","volume":"18","author":"Allegaert","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 1","key":"10.1124\/dmd.123.001270_bib4","first-page":"S42","article-title":"Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes","volume":"59","author":"Bad\u00e9e","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.1109","article-title":"Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver","volume":"105","author":"Bhatt","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2125.1989.tb03548.x","article-title":"Morphine metabolism in children","volume":"28","author":"Choonara","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.1988.tb03330.x","article-title":"Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration","volume":"25","author":"Clausen","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/cpt.2384","article-title":"Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy","volume":"110","author":"Cleary","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0009-9236(01)15882-0","article-title":"Pharmacokinetics and metabolism of intravenous midazolam in preterm infants","volume":"70","author":"de Wildt","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":"Cytochrome P450 3A: ontogeny and drug disposition","volume":"37","author":"de Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00228-009-0741-5","article-title":"Ontogeny of midazolam glucuronidation in preterm infants","volume":"66","author":"de Wildt","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/00003088-200645070-00004","article-title":"A mechanistic approach for the scaling of clearance in children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/bdd.2257","article-title":"Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms","volume":"42","author":"El-Khateeb","year":"2021","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.123.001270_bib14","unstructured":"European Medicines Agency (2016) Guidelines on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation."},{"key":"10.1124\/dmd.123.001270_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/psp4.12144","article-title":"Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter","volume":"6","author":"Emoto","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/bs.apha.2022.05.006","article-title":"Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics","volume":"95","author":"Emoto","year":"2022","journal-title":"Adv Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/psp4.12392","article-title":"A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition","volume":"8","author":"Emoto","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/psp4.12306","article-title":"PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants","volume":"7","author":"Emoto","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.118.082032","article-title":"Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7","volume":"46","author":"Godamudunage","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001270_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2018.09.035","article-title":"Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus","volume":"396","author":"Hamano","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1124\/dmd.123.001270_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jbt.20179","article-title":"Ontogeny of human hepatic cytochromes P450","volume":"21","author":"Hines","year":"2007","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/dmd.123.001270_bib22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bcp.13764","article-title":"Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children","volume":"85","author":"Johnson","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib23","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1124\/dmd.115.068643","article-title":"How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach","volume":"44","author":"Johnson","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001270_bib24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/bja\/89.3.428","article-title":"Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis","volume":"89","author":"Johnson","year":"2002","journal-title":"Br J Anaesth"},{"key":"10.1124\/dmd.123.001270_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children","volume":"45","author":"Johnson","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/psp4.12764","article-title":"Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations","volume":"11","author":"Johnson","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2125.2001.01370.x","article-title":"Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis","volume":"51","author":"Johnson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.1899","article-title":"Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents","volume":"35","author":"Johnson","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.123.001270_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.1875-9114.1985.tb03411.x","article-title":"Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia","volume":"5","author":"Kanto","year":"1985","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.123.001270_bib30","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1124\/dmd.121.000559","article-title":"Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics","volume":"49","author":"Kiss","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001270_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psp4.12479","article-title":"Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation","volume":"9","author":"Kuemmel","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","article-title":"Interaction between grapefruit juice and midazolam in humans","volume":"58","author":"Kupferschmidt","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib33","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/clpt.2012.19","article-title":"Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials","volume":"91","author":"Leong","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.1992.84","article-title":"Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers","volume":"51","author":"Mandema","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/bja\/61.3.302","article-title":"A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery","volume":"61","author":"Mathews","year":"1988","journal-title":"Br J Anaesth"},{"key":"10.1124\/dmd.123.001270_bib36","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.107.015214","article-title":"Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4","volume":"35","author":"Miyagi","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001270_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40262-020-00939-2","article-title":"Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome","volume":"60","author":"Mizuno","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1004","article-title":"Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: An observational, prospective, controlled study","volume":"10","author":"Neupane","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/dmd.123.001270_bib40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.115.068601","article-title":"Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data","volume":"44","author":"Nguyen","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001270_bib41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000480927","article-title":"Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus","volume":"14","author":"Pacifici","year":"1989","journal-title":"Dev Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF00609630","article-title":"Morphine glucuronidation in human fetal and adult liver","volume":"22","author":"Pacifici","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00679782","article-title":"The pharmacokinetics of midazolam in paediatric patients","volume":"37","author":"Payne","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib44","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/00912700122012832","article-title":"The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration","volume":"41","author":"Reed","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF00314967","article-title":"Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration","volume":"41","author":"Rey","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","article-title":"A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data","volume":"53","author":"Salem","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib47","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/psp4.12798","article-title":"Development and application of a pediatric mechanistic kidney model","volume":"11","author":"Salem","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cpt.1990","article-title":"Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants","volume":"109","author":"Salerno","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1213\/00000539-198707000-00007","article-title":"Midazolam as an induction agent in children: a pharmacokinetic and clinical study","volume":"66","author":"Salonen","year":"1987","journal-title":"Anesth Analg"},{"key":"10.1124\/dmd.123.001270_bib50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2011.35","article-title":"Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis","volume":"89","author":"Schmitt","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199631040-00004","article-title":"Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update","volume":"31","author":"Scholz","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001270_bib52","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1124\/dmd.110.035295","article-title":"Metabolism of 1\u2032- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7","volume":"38","author":"Seo","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001270_bib53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.103.054841","article-title":"Developmental expression of the major human hepatic CYP3A enzymes","volume":"307","author":"Stevens","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.123.001270_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","article-title":"Developmental aspects of human hepatic drug glucuronidation in young children and adults","volume":"50","author":"Strassburg","year":"2002","journal-title":"Gut"},{"key":"10.1124\/dmd.123.001270_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/bpb.b14-00566","article-title":"Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation","volume":"38","author":"Takahiro","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.123.001270_bib56","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0022-3476(05)82066-9","article-title":"Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy","volume":"119","author":"Tolia","year":"1991","journal-title":"J Pediatr"},{"key":"10.1124\/dmd.123.001270_bib57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jcph.585","article-title":"Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling","volume":"56","author":"Upreti","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib58","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1111\/bcp.14047","article-title":"Dose-linearity of the pharmacokinetics of an intravenous [14 C]midazolam microdose in children","volume":"85","author":"van Groen","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107541","article-title":"Physiologically-based pharmacokinetic models for children: Starting to reach maturation?","volume":"211","author":"Verscheijden","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.123.001270_bib60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","article-title":"Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children","volume":"194","author":"Vet","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/dmd.123.001270_bib61","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib62","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","article-title":"Noninvasive tests of CYP3A enzymes","volume":"4","author":"Watkins","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.123.001270_bib63","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","article-title":"Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7","volume":"30","author":"Williams","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001270_bib64","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1124\/dmd.106.011387","article-title":"Epirubicin glucuronidation and UGT2B7 developmental expression","volume":"34","author":"Zaya","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"10.1124\/dmd.123.001270_bib65","first-page":"S160","article-title":"Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA\u2019s Office of Clinical Pharmacology","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001270_bib66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/dmd.107.017962","article-title":"Characterization of 1\u2032-hydroxymidazolam glucuronidation in human liver microsomes","volume":"36","author":"Zhu","year":"2008","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:03:53Z","timestamp":1739955833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624010286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0090955624010286"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001270","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}